224 related articles for article (PubMed ID: 18024652)
1. Thrombocytosis and thrombosis.
Vannucchi AM; Barbui T
Hematology Am Soc Hematol Educ Program; 2007; ():363-70. PubMed ID: 18024652
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia and Thrombocytosis.
Parnes A; Ravi A
Prim Care; 2016 Dec; 43(4):589-605. PubMed ID: 27866579
[TBL] [Abstract][Full Text] [Related]
4. [Essential thrombocytosis].
Van Camp G
Acta Clin Belg; 1989; 44(1):31-6. PubMed ID: 2763782
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. Relevance of early diagnosis in polycythemia vera and essential thrombocythemia: A single center's experience.
Lakhwani S; Pardina-Echevarría M; Arcas-Vega R; Díaz-Sánchez OR; Hernández-García MT; Raya JM
Rev Clin Esp (Barc); 2022 Mar; 222(3):169-173. PubMed ID: 34657827
[TBL] [Abstract][Full Text] [Related]
7. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
8. [Role of the activating mutation Val617Phe of Janus kinase 2 gene in myeloproliferative diseases and significance of its detection].
Andrikovics H; Szilvási A; Meggyesi N; Király V; Halm G; Lueff S; Nahajevszky S; Mikala G; Sipos A; Lovas N; Csukly Z; Mátrai Z; Tamáska J; Tordai A; Masszi T
Orv Hetil; 2007 Feb; 148(5):203-10. PubMed ID: 17344140
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.
Thiele J; Kvasnicka HM
Semin Thromb Hemost; 2006 Apr; 32(3):219-30. PubMed ID: 16673276
[TBL] [Abstract][Full Text] [Related]
10. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
11. Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.
Strobbe L; Lestrade P; Hermans MH; Fijnheer R
Ann Hematol; 2007 Nov; 86(11):801-3. PubMed ID: 17703302
[TBL] [Abstract][Full Text] [Related]
12. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis.
Wang JC; Chen C; Novetsky AD; Lichter SM; Ahmed F; Friedberg NM
Am J Med; 1998 May; 104(5):451-5. PubMed ID: 9626028
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
14. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia.
Schwarz J; Pytlík R; Doubek M; Brychtová Y; Dulícek P; Campr V; Kren L; Penka M
Semin Thromb Hemost; 2006 Apr; 32(3):231-45. PubMed ID: 16673277
[TBL] [Abstract][Full Text] [Related]
15. [Investigation and management of patients presenting with thrombocytosis].
Cheminant M; Delarue R
Rev Med Interne; 2013 Aug; 34(8):465-71. PubMed ID: 23498669
[TBL] [Abstract][Full Text] [Related]
16. [Significance of platelet parameters and lactate dehydrogenase level in differential diagnosis for thrombocytosis].
Zhang KJ; Lu QY; Li P; Zhang P; Niu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):972-5. PubMed ID: 20723311
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloproliferative diseases with an elevated platelet count (in excess of 1,000,000/microliter): a clinicopathological study on 46 patients with special emphasis on primary (essential) thrombocythemia.
Thiele J; Moedder B; Kremer B; Zankovich R; Fischer R
Hematol Pathol; 1987; 1(4):227-37. PubMed ID: 3504437
[TBL] [Abstract][Full Text] [Related]
18. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloproliferative disorders (CMPD).
Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
Pathol Res Pract; 1984 Nov; 179(2):131-86. PubMed ID: 6395125
[TBL] [Abstract][Full Text] [Related]
20. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
Thiele J; Funke S; Holgado S; Choritz H; Georgii A
Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
